Sign In
Buy CRBP
$7.38
-0.160 (-2.12%)
At Close: Jun 03, 2026
Corbus Pharmaceuticals Holdings, Inc. (CRBP) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
03:15pm, Thursday, 15'th Jan 2026
Corbus Pharmaceuticals Holdings, Inc. (CRBP) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Corbus Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
07:30am, Monday, 05'th Jan 2026
NORWOOD, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a clinical-stage company focused on oncology and obesity, today announced that Yuval Cohen, Ph.D.
Assenagon Asset Management S.A. Takes Position in Corbus Pharmaceuticals Holdings, Inc. $CRBP
03:20am, Thursday, 25'th Dec 2025
Assenagon Asset Management S.A. purchased a new position in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) in the third quarter, according to its most recent Form 13F filing with the Securities
Corbus Pharmaceuticals Holdings, Inc. (CRBP) Discusses Phase 1a Single-Ascending and Multiple-Ascending Dose Data Transcript
04:42pm, Thursday, 11'th Dec 2025
Corbus Pharmaceuticals Holdings, Inc. (CRBP) Discusses Phase 1a Single-Ascending and Multiple-Ascending Dose Data Transcript
2 Pharma Stocks Pop on Strong Obesity Drug Trial Results
11:16am, Thursday, 11'th Dec 2025
Positive drug trial results are boosting pharmaceutical stocks today, with Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP) and Eli Lilly & Co. (NYSE:LLY) drawing investor attention after encouragin
NORWOOD, Mass., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a clinical-stage company focused on oncology and obesity, today announced the completion of the s
Company will host conference call and live webcast to review and discuss the data at 8:00 am ET Company will host conference call and live webcast to review and discuss the data at 8:00 am ET
Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences
08:00am, Thursday, 06'th Nov 2025
NORWOOD, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) (“Corbus” or the “Company”), an oncology and obesity company, today announced it will be
Corbus Pharmaceuticals: Data Update And Fundraising Efforts Do Not Diminish The Thesis
11:42am, Wednesday, 05'th Nov 2025
Corbus Pharmaceuticals is continuing to march forward with their Nectin-4 ADC, with recent data showcasing impressive tolerability in particular. A recent fundraising for around $75 million was a stro
Corbus Pharmaceuticals Announces Pricing of Public Offering
02:40am, Friday, 31'st Oct 2025
NORWOOD, Mass., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) (“Corbus” or the “Company”), an oncology and obesity company, today announced the pricing
Corbus Pharmaceuticals Announces Proposed Public Offering
04:31pm, Thursday, 30'th Oct 2025
NORWOOD, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) (“Corbus” or the “Company”), an oncology and obesity company, today announced that it pla
Corbus Pharmaceuticals Holdings, Inc. (CRBP) Discusses CRB-701 Data and Insights in Head and Neck Cancer Panel Transcript
05:05pm, Monday, 20'th Oct 2025
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP ) Discusses CRB-701 Data and Insights in Head and Neck Cancer Panel October 19, 2025 4:00 AM EDT Company Participants Yuval Cohen - CEO & Director Do
Corbus Pharmaceuticals Presents CRB-701 Robust Clinical Responses in HNSCC and Cervical Cancers at ESMO25
03:00am, Saturday, 18'th Oct 2025
NORWOOD, Mass., Oct. 18, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company') today announced data from its Phase 1/2 clinical study of CRB-7
FDA Grants Fast Track Designation to Corbus Pharmaceuticals' Nectin-4 Targeting ADC CRB-701 in Head and Neck Squamous Cell Carcinoma
08:00am, Tuesday, 16'th Sep 2025
NORWOOD, Mass., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical stage oncology and obesity company, announced to
Corbus (CRBP) Q2 Loss Beats Estimates
05:41pm, Tuesday, 05'th Aug 2025
Corbus (CRBP) Q2 Loss Beats Estimates
